Henry Schein names Dan Daniel independent chairman
Henry Schein, Inc. reported results of its 2026 Annual Meeting of Stockholders and a leadership change on its Board.
Rhea-AI Filing Summary
Henry Schein, Inc. reported results of its 2026 Annual Meeting of Stockholders and a leadership change on its Board. Stockholders elected ten incumbent directors for terms expiring in 2027, approved on an advisory basis the 2025 compensation of Named Executive Officers, and ratified BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 26, 2026. A shareholder proposal to Govern by Majority Vote received substantial support but did not pass, with 59,487,608 votes for, 43,707,406 against, 154,122 abstentions and 5,933,309 broker non-votes. The Board elected William K. “Dan” Daniel as Independent Chairman effective May 21, 2026, succeeding long-time director Stanley M. Bergman, who retired from the Board after 44 years and was named Chairman Emeritus. The company notes that its sales reached $13.2 billion in 2025 and have grown at a compound annual rate of approximately 11.0 percent since becoming a public company in 1995.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
say-on-pay financial
independent registered public accounting firm financial
Majority Vote regulatory
Strategic Partnership Agreement financial
EU Medical Device Regulation regulatory
forward-looking statements regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Henry Schein (HSIC) stockholders approve at the 2026 Annual Meeting?
How did Henry Schein (HSIC) stockholders vote on the say-on-pay proposal for 2025 compensation?
Who is Henry Schein’s new Independent Chairman of the Board?
What governance change occurred at Henry Schein (HSIC) with Stan Bergman’s retirement?
How large is Henry Schein’s business based on recent reported sales?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On May 21, 2026, at the Henry Schein, Inc. (the “Company”) 2026 Annual Meeting of Stockholders (the “Annual Meeting”), the Company’s stockholders considered: (1) a proposal to consider approval of the election of ten incumbent directors of the Company for terms expiring in 2027; (2) a proposal to consider approval, by non-binding vote, of the 2025 compensation paid to the Company’s Named Executive Officers (as defined in the proxy statement) (commonly known as a “say-on-pay” proposal); (3) a proposal to consider the ratification of the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 26, 2026; and (4) a proposal to consider approval, by non-binding vote, of a shareholder proposal to Govern by Majority Vote. The voting results at the Annual Meeting, with respect to each of the matters described above, are set forth below.
| 1. | The ten incumbent directors of the Company were elected to serve for terms expiring in 2027 based upon the following votes: |
| For | Against | Abstain | Broker Non-Votes |
|||||||||||||
| Mohamad Ali |
102,451,460 | 776,720 | 120,956 | 5,933,309 | ||||||||||||
| William K. “Dan” Daniel |
99,760,754 | 3,561,487 | 26,895 | 5,933,309 | ||||||||||||
| Deborah Derby |
102,226,374 | 1,032,737 | 90,025 | 5,933,309 | ||||||||||||
| Carole T. Faig |
103,187,930 | 106,503 | 54,703 | 5,933,309 | ||||||||||||
| Kurt P. Kuehn |
102,824,264 | 496,439 | 28,433 | 5,933,309 | ||||||||||||
| Philip A. Laskawy |
97,174,831 | 6,158,597 | 15,708 | 5,933,309 | ||||||||||||
| Max Lin |
79,900,114 | 23,411,010 | 38,012 | 5,933,309 | ||||||||||||
| Frederick M. Lowery |
103,001,977 | 332,786 | 14,373 | 5,933,309 | ||||||||||||
| Anne H. Margulies |
103,199,853 | 93,763 | 55,520 | 5,933,309 | ||||||||||||
| Reed V. Tuckson, M.D., FACP |
103,198,021 | 107,489 | 43,626 | 5,933,309 | ||||||||||||
| 2. | The 2025 compensation paid to the Company’s Named Executive Officers, commonly known as the “say-on-pay” proposal, was approved, by non-binding vote, based upon the following votes: |
| For |
Against |
Abstain |
Broker Non-Votes | |||
| 101,159,461 | 2,110,298 | 79,377 | 5,933,309 |
| 3. | The selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 26, 2026 was ratified based upon the following votes: |
| For |
Against |
Abstain | ||
| 107,298,836 | 1,805,825 | 177,784 |
| 4. | The shareholder proposal to Govern by Majority Vote was approved, by non-binding vote, based upon the following votes: |
| For |
Against |
Abstain |
Broker Non-Votes | |||
| 59,487,608 | 43,707,406 | 154,122 | 5,933,309 |
| Item 7.01. | Regulation FD. |
On May 22, 2026, the Company issued a press release (the “Press Release”) announcing the election of William K. “Dan” Daniel as Independent Chairman of the Company’s Board of Directors. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01 and the Press Release attached as Exhibit 99.1 are considered furnished to the Securities and Exchange Commission and are not deemed filed for purposes of Section 18 of the Exchange Act.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| 99.1 | Press Release, dated May 22, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HENRY SCHEIN, INC. (Registrant) | ||||||
| Date: May 22, 2026 | By: | /s/ Kelly Murphy | ||||
| Kelly Murphy | ||||||
| Senior Vice President and General Counsel | ||||||
Exhibit 99.1
FOR IMMEDIATE RELEASE
HENRY SCHEIN ANNOUNCES THE ELECTION OF WILLIAM K. “DAN” DANIEL AS INDEPENDENT CHAIRMAN OF THE BOARD
MELVILLE, N.Y., May 22, 2026 – Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary contributions to the Company.
Mr. Daniel joined the Henry Schein Board of Directors in May 2025. He possesses decades of board and global executive leadership experience in healthcare and industrial sectors, including serving for 14 years as Executive Vice President at Danaher Corporation (NYSE: DHR), where he oversaw multiple business segments including Danaher’s dental portfolio. Mr. Daniel also played a key role in advancing Danaher’s business systems and culture, while also serving as a Board Director at Envista Holdings Corporation (NYSE: NVST) when it was spun off from Danaher.
“I am deeply honored to assume the role of Chairman and am committed to building upon the extraordinary foundation that Stan Bergman and Team Schein established over his tenure,” said Mr. Daniel. “Stan’s strategic leadership, sound judgment, and unwavering dedication to Henry Schein’s mission have helped shape this company into the leading industry provider of products, services, and technology platforms for healthcare customers. His contributions to shareholders, customers, supplier partners, Team Schein Members, and society are profound and enduring. I look forward to supporting this legacy with the Board as we enter an exciting new chapter of growth.”
Stan Bergman said, “It has been an honor to lead Team Schein and serve as Chairman of the Board. I have worked with Dan for many years and have huge respect for his business acumen and leadership. The Company is in good hands, and I look forward to continuing to support Henry Schein’s continuing success as Chairman Emeritus.”
Fred Lowery, Chief Executive Officer of Henry Schein, said, “On behalf of Team Schein, I want to express our profound gratitude to Stan for his remarkable contributions over more than four decades. His transformative leadership positions the Company for tremendous growth, and we wish Stan all the best in this well-deserved next chapter. I am also delighted to welcome Dan Daniel as Chairman of the Board. Dan’s deep understanding of our business and the markets we serve, combined with his distinguished track record, will be instrumental as we execute on our long-term strategy of building the healthcare industry’s most trusted and comprehensive platform of integrated solutions—empowering practitioners to optimize their business operations while advancing the quality, accessibility, and outcomes of patient care.”
- 1 -
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a products, services, and technology platforms company for healthcare customers. With more than 25,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our main distribution centers.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 34 countries and territories. The Company’s sales reached $13.2 billion in 2025, and have grown at a compound annual rate of approximately 11.0 percent since Henry Schein became a public company in 1995.
For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.
Cautionary Note Regarding Forward-Looking Statements
In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: our dependence on third parties for the manufacture and supply of our products and where we manufacture products, our dependence on third parties for raw materials or purchased components; risks relating to the achievement of our strategic growth objectives, including anticipated results of restructuring and value creation initiatives; risks related to the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025; transitions in senior company leadership and the Board of Directors (including, without limitation, the transition to a new Chief Executive Officer and a new Chairman of the Board of Directors); our ability to develop or acquire and maintain and protect new products (particularly technology and specialty products) and services and utilize new technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal, regulatory, compliance, financial and human resources functions
- 2 -
in connection with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; risks related to activist investors; security risks associated with our information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; political, economic, and regulatory influences on the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers, and increases in fuel and energy costs; changes in laws and policies governing manufacturing, development and investment in territories and countries where we do business; general global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment (and corresponding increase in under-insured populations), consumer confidence, sovereign debt levels, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies and changes to other economic indicators failure to comply with existing and future regulatory requirements, including relating to health care; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation, changes in tax rates and availability of certain tax deductions; risks related to product liability, intellectual property and other claims; risks associated with customs policies or legislative import restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters; risks associated with our global operations; the threat or outbreak of war (including, without limitation, geopolitical wars), terrorism or public unrest (including, without limitation, the wars in Ukraine and Iran, the Israel-Gaza war and other unrest and threats in the Middle East and the possibility of a wider European or global conflict); changes to laws and policies governing foreign trade, tariffs and sanctions or greater restrictions on imports and exports, including changes to international trade agreements and the current imposition of (and the potential for additional) tariffs by the U.S. on numerous countries and retaliatory tariffs; supply chain disruption; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our senior management, employee hiring and retention, increases in labor costs or health care costs, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.
| CONTACTS: | Investors |
| Ronald N. South |
| Senior Vice President and Chief Financial Officer |
| ronald.south@henryschein.com |
| (631) 843-5500 |
| Graham Stanley |
| Vice President, Investor Relations and Strategic Financial Project Officer |
| graham.stanley@henryschein.com |
| (631) 843-5500 |
| Media |
| Tim Vassilakos |
| Vice President, Global Corporate Communications |
| timothy.vassilakos@henryschein.com |
| (516) 510-0926 |
- 3 -